<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04540874</url>
  </required_header>
  <id_info>
    <org_study_id>1371-0003</org_study_id>
    <nct_id>NCT04540874</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 894416 Versus Placebo in Healthy Male Japanese Subjects (Single-blind, Randomized, Placebo-controlled Within Dose Group)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to investigate the safety, tolerability and pharmacokinetics&#xD;
      of BI 894416 in healthy Japanese male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to company decision&#xD;
  </why_stopped>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Actual">November 12, 2020</completion_date>
  <primary_completion_date type="Actual">November 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage [%] of subjects with drug related adverse events</measure>
    <time_frame>up to 17 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-âˆž)</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 894416</intervention_name>
    <description>BI 894416</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history, including a medical examination, vital signs (Blood pressure&#xD;
             (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests&#xD;
&#xD;
          2. Japanese ethnicity, according to the following criteria:&#xD;
&#xD;
             - born in Japan, have lived outside of Japan &lt;10 years, and have parents and&#xD;
             grandparents who are Japanese&#xD;
&#xD;
          3. Age of 20 to 45 years (inclusive) at screening&#xD;
&#xD;
          4. BMI of 18.5 to 25.0 kg/m2 (inclusive) at screening&#xD;
&#xD;
          5. Signed and dated written informed consent prior to admission to the trial, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          6. Subjects who agree to minimize the risk of making their partner pregnant by fulfilling&#xD;
             any of the following criteria starting from the first administration of trial&#xD;
             medication until 90 days after last administration of trial medication&#xD;
&#xD;
               -  Use of adequate contraception, any of the following methods plus condom:&#xD;
&#xD;
        intrauterine device, combined oral contraceptives that started at least 2 months prior to&#xD;
        the first drug administration&#xD;
&#xD;
          -  Vasectomized (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
          -  Surgical sterilization (including bilateral tubal occlusion, hysterectomy or bilateral&#xD;
             oophorectomy) of the subject's female partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 50 to 90 bpm&#xD;
&#xD;
          3. Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          4. Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication, except appendectomy or simple&#xD;
             hernia repair&#xD;
&#xD;
          7. Diseases of the central nervous system, including but not limited to, any kind of&#xD;
             seizures or stroke, and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further&#xD;
             exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Hospital Tokyo</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

